Paper Details

  1. Home
  2. Paper Details

Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine.

Author: CarmichaelJ

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Pancreatic cancer has a very poor prognosis, with most patients surviving only a few months. While many chemotherapy drugs have been tried, gemcitabine has shown the most promise. Gemcitabine, a new type of chemotherapy drug, has shown modest tumor shrinkage in studies, but importantly, it has also helped control symptoms and improve quality of life for many patients. A large study comparing gemcitabine to another chemotherapy drug found that gemcitabine resulted in higher response rates, better symptom control, and longer survival, although the overall survival remains poor. Gemcitabine is a valuable option for treating pancreatic cancer, providing significant benefit to about a quarter of patients. Further research is needed to develop more effective treatments, potentially combining gemcitabine with other drugs.
Paper Details　
Original Abstract of the Article :
The prognosis for patients with pancreatic cancer remains extremely poor. A minority are surgically resectable, but the remainder suffer problems from locally invasive disease and also metastatic spread. Median survival in these patients approximates 4 months, with limited systemic options. Many che...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000201493

データ提供：米国国立医学図書館（NLM）

Gemcitabine: A Beacon of Hope for Pancreatic Cancer

This research focuses on the clinical response benefit of gemcitabine, a chemotherapy drug, in patients with advanced pancreatic cancer, a notoriously aggressive disease with a dismal prognosis. The study explores the role of gemcitabine in improving survival and symptom control in these patients, who often have limited treatment options. The researchers reviewed multiple clinical trials evaluating gemcitabine in patients with advanced pancreatic cancer, comparing its effectiveness to other chemotherapy agents.

Gemcitabine: A New Standard in Pancreatic Cancer Treatment

The study highlights the promising results of gemcitabine, demonstrating a significant improvement in response rate, symptom control, and survival compared to other chemotherapy agents. These findings established gemcitabine as the first agent to achieve a statistically significant benefit in advanced pancreatic cancer, offering a ray of hope for these patients.

Pancreatic Cancer: Navigating a Challenging Terrain

This research underscores the importance of finding effective treatments for pancreatic cancer, a devastating disease that often presents significant challenges. Gemcitabine offers a promising therapeutic option, but the study also emphasizes the need for further research to explore combination chemotherapy regimens and improve outcomes for these patients.

Dr. Camel's Conclusion

This research sheds light on the potential of gemcitabine as a valuable treatment option for patients with advanced pancreatic cancer. While the prognosis remains challenging, gemcitabine has shown significant promise in improving survival and symptom control, offering a beacon of hope for these patients and a crucial step forward in the fight against this aggressive disease.
Date :
  1. Date Completed 1998-03-11
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

9438594

DOI: Digital Object Identifier

10.1159/000201493

Related Literature

Article Analysis
・Effective treatment of pancreatic cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.